Table 3.
Monitoring recommendations for risperidone (modified recommendations developed from ADA, APA [2004])
| Measure | Baseline | 1 Month | 2 Months | 3 Months | 4 Months | Yearly |
|---|---|---|---|---|---|---|
| Personal/Family Hxa | X | X | ||||
| Vitals | Every visit | |||||
| BMI (ht/wt) | Every visit | |||||
| Waist circumference | X | X | ||||
| Blood pressure | X | X | X | |||
| Fasting plasma glucose | X | X | X | |||
| Fasting lipid profile | X | X | X | |||
| Prolactin (a.m. preferred)b | Xb | X | ||||
| LFTs | X | |||||
| CBC/dif | X | |||||
| Electrolytes | X | |||||
| AIMS/EPS | X | Increase frequency to monthly if exhibiting signs of tardive dyskinesia | X | |||
| Drug interactions | X | After dose changes or when considering additional agents | ||||
a
Assess for history of cardiovascular disease, diabetes, dyslipidemia, obesity.
b
Follow-up prolactin indicated if signs of breast tenderness, gynecomastia (males), menstrual changes/irregularities (not associated with normal development), or galactorrhea.
Abbreviations: Hx, history; Ht, height; Wt, weight; LFTs, liver function tests; CBC/dif, complete blood count with differential.